Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins.

IF 1.5 4区 医学 Q3 PARASITOLOGY
Tycha Bianca Sabaini Pavan, Leonardo Maia Leony, Wayner Vieira de Souza, Emily Ferreira Santos, Ramona Tavares Daltro, Natalia Erdens Maron Freitas, Larissa Carvalho Medrado Vasconcelos, Fernanda Lopes Habib, Angelo Antonio Oliveira Silva, Paola Alejandra Fiorani Celedon, Daniel Dias Sampaio, Nilson Ivo Tonin Zanchin, Silvia Andrea Longhi, Fred Luciano Neves Santos
{"title":"Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins.","authors":"Tycha Bianca Sabaini Pavan, Leonardo Maia Leony, Wayner Vieira de Souza, Emily Ferreira Santos, Ramona Tavares Daltro, Natalia Erdens Maron Freitas, Larissa Carvalho Medrado Vasconcelos, Fernanda Lopes Habib, Angelo Antonio Oliveira Silva, Paola Alejandra Fiorani Celedon, Daniel Dias Sampaio, Nilson Ivo Tonin Zanchin, Silvia Andrea Longhi, Fred Luciano Neves Santos","doi":"10.14411/fp.2024.004","DOIUrl":null,"url":null,"abstract":"<p><p>Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.</p>","PeriodicalId":55154,"journal":{"name":"Folia Parasitologica","volume":"71 ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Parasitologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14411/fp.2024.004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.

使用克氏锥虫嵌合体蛋白治疗慢性南美锥虫病后的治愈标准。
南美锥虫病(CD)是一种被忽视的疾病,由南美锥虫(Trypanosoma cruzi Chagas,1909 年)引起。病因治疗可采用两种药物:苯并咪唑或尼福霉素。在根除这一疾病方面还存在一些不足。目前还没有一种检测方法可以有效评估治疗后的治愈率。目前,抗 T. cruzi 抗体滴度的下降是通过传统的血清学检测来评估的,这可能需要数年时间。然而,必须继续寻找新的治愈标志物来填补这一空白。本研究旨在利用嵌合蛋白评估被诊断为 CD 的慢性患者在接受苯并咪唑治疗后血清滴度的下降情况。这是一项前瞻性横断面队列研究,研究对象是2000年至2004年间接受过苯尼达唑治疗的阿纳图亚地区(阿根廷)的克鲁兹绦虫阳性患者。研究人员在治疗前(第零天)和治疗结束后(2、3、6、12、24 和 36 个月)采集了 10 名患者的血清样本。为了检测抗克鲁兹绦虫抗体,使用两种嵌合重组蛋白(IBMP-8.1 和 IBMP-8.4)作为抗原进行间接 ELISA 检测。采用弗里德曼检验法评估了治疗前后各组反应指数的变化。所有参与者在接受苯并咪唑治疗后,血清滴度都有所下降,尤其是 IBMP-8.1。然而,由于样本数量较少,随访时间较短,因此得出该分子可作为持续治愈标准的结论还为时过早。还需要进一步的研究来验证基于这些或其他生物标志物的测试,以证明寄生虫治愈。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Folia Parasitologica
Folia Parasitologica 医学-寄生虫学
CiteScore
2.70
自引率
0.00%
发文量
25
审稿时长
>12 weeks
期刊介绍: FOLIA PARASITOLOGICA, issued in online versions, is an international journal that covers the whole field of general, systematic, ecological and experimental parasitology. It publishes original research papers, research notes and review articles. Contributions from all branches of animal parasitology, such as morphology, taxonomy, biology, biochemistry, physiology, immunology, molecular biology and evolution of parasites, and host-parasite relationships, are eligible. Novelty and importance in the international (not local or regional) context are required. New geographical records of parasites, records of new hosts, regional parasite and/or host surveys (if they constitute the principal substance of manuscript), local/regional prevalence surveys of diseases, local/regional studies on epidemiology of well known diseases and of parasite impact on human/animal health, case reports, routine clinical studies and testing of established diagnostic or treatment procedures, will not be considered. One species description will also not be considered unless they include more general information, such as new diagnostic characters, host-parasite associations, phylogenetic implications, etc. Manuscripts found suitable on submission will be reviewed by at least two reviewers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信